Kinepict Health Ltd. today announced that it has received US FDA 510(k) clearance for its Kinepict Medical Imaging Tool (KMIT) software, which uses the company’s proprietary, ground-breaking Digital Variance Angiography (DVA).
| BUDAPEST, Hungary, March 10, 2020 / B3C newswire / -- Kinepict Health Ltd. today announced that it has received US FDA 510(k) clearance for its Kinepict Medical Imaging Tool (KMIT) software, which uses the company’s proprietary, ground-breaking Digital Variance Angiography (DVA). Kinepict’s DVA technology revolutionizes the calculation of X-ray angiography images, innovating a field in which the fundamental principles of data analysis were unchanged in the past four decades. The proprietary DVA algorithm uses advanced statistical methods to visualizes blood vessels by identifying contrast-induced changes in the X-ray angiography image series. First clinical validations show that DVA provides superior image quality compared to the state-of-the-art Digital Subtraction Angiography (DSA). The dramatically improved image quality provided by DVA has the potential to make X-ray angiography safer and more powerful. Thus, the KMIT software can overcome the typical trade-off between increased X-Ray dose vs. increased contrast media. The following indications have already been clinically validated, and several other clinical validations are underway: (1) Using DVA instead of DSA greatly improves image quality (2.5 to 10 times better contrast-to-noise ratio) for both positive (iodinated) and negative (CO2) contrast media. The recent FDA clearance paves the way for a timely start of launch of the technology onto the US market. The Company is open for talks with potential partners from the imaging industry or other health service organizations active in the angiography field. About Kinepict Health Ltd. Contact Kinepict Health Ltd. Keywords: Angiography, Digital Subtraction; X-Rays; Computers; Software Published by B3C newswire and shared through Newronic®
|
